Clinical Characteristics and Progression of 2019 Novel Coronavirus-Infected Patients Concurrent Acute Respiratory Distress Syndrome

Yanli Liu, MD[1,*]; Wenwu Sun, MD[1,*], Liangkai Chen, PhD[2,#], Yujun Wang, MD[1], Lijuan Zhang, MD[1], Li Yu, MD[1,#].

[1]Intensive Care Unit, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

[2]Department of Nutrition and Food Hygiene, Hubei Key Laboratory of Food Nutrition and Safety, Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

*The first two authors contributed equally to this article.

#Corresponding authors:

Liangkai Chen, Email: clk@hust.edu.cn;

Li Yu, Email: yuliwhzxyy@163.com.

Word count: 2,306

No. of Tables: 3

No. of Figures: 2

Abstract

Background: In December 2019, the outbreak of novel coronavirus (2019-nCoV) infection lead to a cluster of pneumonia cases. We report the clinical characteristics of 2019-nCoV infected patients with acute respiratory distress syndrome (ARDS) and further investigate the treatment and the progression of the disease.

Methods: The longitudinal study included 109 patients with novel coronavirus-infected pneumonia (COVID-19) admitted to the Central Hospital of Wuhan between January 2 and February 1, 2020. Patients were followed up to February 12, 2020. Epidemiological, clinical, and laboratory characteristics, treatment, and outcomes data were collected from electronic medical records. The difference in treatment and progression between patients with ARDS and without ARDS was compared.

Results: Among 109 patients with COVID-19, the median age was 55 years (IQR, 43-66 years; range, 22-94 years), and 59 (54.1%) patients were men. The median hospital days were 15 days (interquartile range, 11-24 days), and 31 (28.4%) patients had died and 78 (71.6%) survived. Among them, 53 (48.6%) patients developed ARDS. Compared with non-ARDS patients, patients with ARDS were more likely to have coexisting conditions, including diabetes (20.8% *vs.* 1.8%), cerebrovascular (11.3% *vs.* 0%) and chronic kidney disease (15.1% *vs.* 3.6%). Compared with patients with mild ARDS (n = 1/19 [5.3%]), those with moderate and severe ARDS had a higher mortality rate (n = 15/24 [62.5%] for moderate ARDS and n = 10/10 [100.0%] for severe ARDS). The mortality rate increased concomitantly with the severity of ARDS. We have not observed a significant effect of antivirus, glucocorticoid, or immunoglobulin treatment on survival in patients with ARDS.

Conclusions: Our findings indicated that 2019-nCoV infected patients with moderate-to-severe ARDS had higher mortality rates and the beneficial effects of current treatments were not satisfactory, which are warranted attention from clinicians.

Key words: Acute respiratory distress syndrome; mortality; novel coronavirus-infected pneumonia; 2019 novel coronavirus

Introduction

In December 2019, a series of pneumonia cases emerged in Wuhan with 11 million people located in central China, which was related to the exposure of the Huanan Seafood Wholesale Market [1,2]. Early reported cases with clinical manifestations resembling viral pneumonia were identified as "pneumonia of unknown etiology" [3]. On January 3, 2020, samples from bronchoalveolar lavage fluid of patients in Wuhan indicated a novel coronavirus, which was called the 2019 novel coronavirus (2019-nCoV) and then "pneumonia of unknown etiology" was named novel coronavirus-infected pneumonia (COVID-19) [2,4]. The disease has rapidly spread and massive COVID-19 cases have been confirmed in Wuhan and some exported cases have been identified in other Chinese cities and other countries [5-8]. As of February 15, 2020, a total of 68,500 confirmed cases and 1,665 death cases have been reported.

Existing evidence demonstrated the clinical characteristics of infected patients and human-to-human transmission capability. The first reported 41 COVID-19 patients were characterized by fever, cough, myalgia, fatigue, diarrhea, dyspnea, lymphopenia, and abnormal chest computed tomographic (CT) findings. Complications including acute respiratory distress syndrome (ARDS), shock, acute cardiac injury, and acute kidney injury were associated with high mortality [4]. Subsequently, Wang *et al.* [9] reported 138 hospitalized patients with COVID-19 and suggested that patients admitted to the intensive care unit (ICU) were older and had more underlying comorbidities and complications than those who were not admitted to the ICU. Clinically, we found that COVID-19 patients progressed rapidly, and most patients experienced severe respiratory failure. However, the evidence of treatment and progression between ARDS

and non-ARDS cases was scarce. Here, we aim to describe the clinical features of 109 hospitalized COVID-19 patients and further discuss the clinical characteristics, treatment, and progression of patients who developed into ARDS.

Methods

Study Population

Patients with COVID-19 admitted to the Central Hospital of Wuhan between January 2 and February 1, 2020 were enrolled. The diagnostic criteria of the disease was based on virus RNA detection, clinical characteristics, chest imaging, and the ruling out common pathogen, according to the World Health Organization interim guidance [10]. Patients with malignant tumors, post craniocerebral operation, died on admission, and transferred to other medical institutions were excluded. The clinical outcomes of patients were followed up to February 12, 2020. Data were anonymous, and the requirement for informed consent was waived. This study was approved by the Ethics Committees of Tongji Medical College, Huazhong University of Science and Technology.

Data collection

Case report forms, nursing records, laboratory findings, and radiological characteristics were reviewed. Epidemiological, clinical, laboratory, radiological characteristics, treatment, and outcomes data were collected onto standardized forms from electronic medical records. Two senior physicians independently reviewed the data. Information on demographic data, symptoms, underlying comorbidities, chest CT scans, and laboratory results were included. All

96 treatment measures were collected during hospitalization, including antiviral therapy,
97 antibacterial therapy, corticosteroid therapy, immune support therapy, and respiratory support.
98 The time of disease onset was defined as the day of symptom onset. The time from first
99 symptom to fever clinics, hospital admission, and clinical outcomes were recorded. A
100 confirmed respiratory tract specimen was defined as positive for 2019-nCoV. Repeated tests
101 for 2019-nCoV were done in confirmed patients to show viral clearance before hospital
102 discharge. We applied the Berlin classification to determine presence and severity of ARDS [11].
103 Acute Physiology and Chronic Health Evaluation II scores (APACHE II), Sequential Organ
104 Failure Assessment (SOFA), and CURB-65 criteria were determined within 24h after
105 admission.
106

107 **Detection of coronavirus by real-time RT-PCR**

108 Throat swab samples were collected from suspected patients and the method of virus RNA
109 detection was reported [9]. In brief, the presence of 2019-nCoV in respiratory specimens was
110 detected by real-time RT-PCR methods. Two target genes, including open reading frame lab
111 (ORF1ab) and nucleocapsid protein (N), were used and the sequences were as follows: Target
112 1 (ORF1ab): forward primer CCCTGTGGGTTTTACACTTAA; reverse primer
113 ACGATTGTGCATCAGCTGA. Target 2 (N): forward primer
114 GGGGAACTTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTCAAGCTG.
115 The real-time RT-PCR assay was performed according to the manufacturer's protocol (Beijing
116 Genomics Institution and Geneodx biotechnology Co. Ltd). Positive test results for two target
117 genes would be considered to be laboratory-confirmed infection.

Statistical analysis

For continuous variables, normally distributed variables presented as mean ± SD and were compared by Student's t-test, while median (interquartile range [IQR]) and the Mann–Whitney test (when comparing 2 groups) or the Kruskal–Wallis test were used for skew distributed ones. For categorical variables, the Chi-square test or the Fisher's exact probability test were used to compare the differences between groups. The Kaplan–Meier methods were used for survival plotting and log-rank test for comparison of survival curves. The dynamic trajectory in laboratory parameters was plotted using GraphPad Prism 8 (GraphPad Software, Inc), and the differences in these indices between ARDS and non-ARDS groups over time were examined by generalized linear mixed models. All of the analyses were performed with the statistical software packages R (http://www.R-project.org, The R Foundation) and the EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA) with a two-sided significance threshold of $P < 0.05$.

Results

Clinical Characteristics

Between January 2, 2020 and February 1, 2020, 109 patients with COVID-19 were included from the Central Hospital of Wuhan (**Table 1**). The median age was 55 years (IQR, 43-66 years; range, 22-94 years), and 59 (54.1%) patients were men. Among them, 76 (69.7%) patients had underlying comorbidities, including hypertension (33.9%), diabetes (11.0%), and chronic kidney disease (9.2%). The most common symptoms at illness onset were fever (82.6%), dry

140 cough (61.5), and fatigue (56.9%). Compared with non-ARDS patients, patients who
141 developed into ARDS were more likely to have coexisting conditions, including diabetes (20.8%
142 *vs.* 1.8%), cerebrovascular (11.3% *vs.* 0%) and chronic kidney disease (15.1% *vs.* 3.6%). The
143 median time from symptom onset to fever clinics and hospital admission were 4 days (IQR, 2-
144 6 days) and 7 days (IQR, 5-9 days), respectively. The average hospital days were 15 days (IQR,
145 11-24 days). The first virus RNA detection rate was 24.8% in fever clinics and all patients were
146 reconfirmed by repeated virus RNA testing after admission. Abnormalities in chest CT images
147 on admission were detected in all patients. Of the 109 patients, 100 (91.7%) had bilateral
148 involvement. High-flow oxygen ventilation was required in 28 patients (25.7%), of which 26
149 had ARDS. During the follow-up period, 31 (28.4%) patients had died and 78 (71.6%) survived
150 and were discharged from hospital.
151
152 **Severity of Illness Scores, Blood Gas Analysis, and Laboratory Findings**
153 Laboratory findings on admission are shown in **Table 2** according to patients' ARDS severity.
154 ARDS patients were accompanied by a significant lymphopenia on admission. In addition, C-
155 reactive protein (CRP), procalcitonin, and lactate levels were higher in ARDS patients (median
156 CRP level 4.9 [IQR, 2.7-6.5] mg/dL; median procalcitonin level 0.1 [IQR, 0.1-0.4] ng/mL;
157 median lactate level 1.6 [IQR, 1.1-2.2] mmol/L) compared with patients without ARDS
158 (median CRP level 2.0 [IQR, 0.9-3.2] mg/dL, P <0.001; median procalcitonin level 0.1 [IQR,
159 0.0-0.1] ng/mL, P <0.001; median lactate level 1.1 [IQR, 0.8-1.6] mmol/L, P <0.001). We also
160 observed a significant increase of serum fibrinogen, D-dimer, and lactate dehydrogenase in
161 ARDS patients compared with those without ARDS. On the day of admission, compared with

162 non-ARDS patients, ARDS patients had higher APACHE II, SOFA, and CURB criteria scores
163 (P <0.001). The dynamic trajectory in 9 laboratory parameters were tracked on day 1, day 3,
164 day 7, and day 14, respectively (**Figure 1**).
165

166 **Clinical Profile and Progression of ARDS Patients**

167 We further described the clinical characteristics, treatments, and progressions of 53 patients
168 with ARDS according to the severity (**Table 3**). Compared with patients with mild ARDS (n =
169 1/19 [5.3%]), those with moderate and severe ARDS had a higher mortality rate (n = 15/24
170 [62.5%] for moderate ARDS and n = 10/10 [100%] for severe ARDS). The increase in
171 APACHE II, SOFA, and CURB criteria scores occurred concomitantly with the severity of
172 ARDS. Most patients were administered with antibiotics therapy and antivirus therapy
173 (ribavirin, 46 [86.8%]; oseltamivir, 14 [26.4%]; arbidol, 6 [11.3%]). In addition, 37 (69.8%) of
174 them received glucocorticoid therapy and 29 patients (54.7%) were treated with intravenous
175 immunoglobulin. Further survival analysis showed that neither antivirus, glucocorticoid, nor
176 immunoglobulin treatment had a significant effect on the survival of patients with ARDS
177 (**Figure 2**, all log-rank tests P >0.05).
178

179 **Discussion**

180 The current study compared the clinical characteristics of 109 COVID-19 patients with and
181 without ARDS, and further investigated the treatment and the progression of ARDS. In addition
182 to the difference in clinical characteristics, our results indicated that COVID-19 patients with
183 ARDS had a higher mortality rate compared with non-ARDS patients. We did not observe any

apparent effect of current clinical treatments on in-hospital mortality in ARDS patients. These findings underscored the need for enhanced clinical attention towards COVID-19 patients who were at high risk of ARDS.

To the best of our knowledge, the current study is the first to investigate the clinical characteristics and progression of 2019-nCoV infected patients with ARDS. We observed that the patients concurrent ARDS were older and had more comorbidities than those without ARDS. Our analysis showed that patients with moderate and severe ARDS had a higher mortality rate, which requires clinicians to pay close attention to the clinical progression of such cases. These data were consistent with the current report that showed age and comorbidity are risk factors for poor clinical outcomes [9]. Compared with patients without ARDS, patients concurrent ARDS have elevated levels of CRP, procalcitonin, and D-dimer, and lower lymphocyte counts, suggesting a persistent inflammatory response, coagulation activation, and immunosuppression in the course of disease progression. Although these laboratory indices showed a statistically significant change with time and the severity of ARDS, their clinical relevance and predictive value remain to be determined. Unlike previous reports [4,9], we did not observe differences in liver injury and kidney injury indices between patients with and without ARDS. In addition, the first nucleic acid positive rate in our population was only 24.8%. Such a high false negative rate may be caused by improper collection of throat swab samples or insufficient viral load, supporting that nucleic acid detection and diagnosis from throat swabs cannot be used as the only evidence recommended by the current guidelines.

206 So far, there is still lack of effective drugs for clinical treatment of COVID-19. Currently, the
207 mainstream treatment for most COVID-19, especially combined with ARDS, is still antiviral
208 therapy, while evidence from previous study and our findings did not observe the benefits from
209 this treatment in most cases [12]. Given that remdesivir was an effective antiviral agent against
210 SARS-CoV and MERS-CoV infections reported in previous studies [13,14], a randomized
211 controlled trial has been launched to assess the efficacy and safety in critically ill patients with
212 severe 2019-nCoV respiratory disease (NCT04257656). Prior studies demonstrated that
213 increased amounts of proinflammatory cytokines were associated with lung damage and
214 cytokine storm was associated with disease severity [4,15]. Corticosteroids were commonly used
215 to reduce inflammatory-induced lung injury. Among 34 COVID-19 with moderate to severe
216 ARDS in the present study, more than 70 percent of patients received glucocorticoid therapy.
217 Nevertheless, the survival curve suggested the treatment might not reduce the mortality of
218 patients with ARDS, which supported the current view of "not support corticosteroid treatment"
219 in clinical practice [16]. The use of immunotherapeutic agents to combat inflammatory mediator
220 excesses has been of concern to clinicians, while the evidence of its benefits remained
221 insufficient and inconclusive [17]. In our study, intravenous immunoglobulins did not show
222 clinically significant survival benefits. In addition, we found that the disease progressed rapidly
223 in ARDS patients and most patients developed severe respiratory failure. High flow oxygen
224 supplementation was often applied to improve respiratory function. Future studies are
225 warranted to investigate the impact of early oxygen delivery, oxygen delivery pathways, and
226 ventilator treatment time on clinical outcomes of COVID-19 patients with ARDS.
227

228 In December 2019, Wuhan became the center of the outbreak of 2019-nCoV infection. The
229 number of patients with COVID-19 has dramatically increased. In order to control the epidemic,
230 a large number of hospitals have been requisitioned as designated hospitals for the infectious
231 disease in the short term. However, due to inadequate infrastructure, insufficient staff, and the
232 lack of protective isolation measures for highly infectious cases, most hospitals cannot meet
233 the treatment conditions of critically ill patients. Because of the continuous increase in the
234 number of patients, there is not enough invasive ventilation and extracorporeal membrane
235 oxygenation (ECMO) equipment available to large quantity of patients in some designated
236 hospitals. From a policy perspective, the government should provide capital, technology, and
237 manpower to curb the epidemic, including material resources, human resources, mental
238 resources and others. Meanwhile, in the front-line epidemic area, limited medical resources
239 should be allocated reasonably and effectively.
240
241 The present study is subjected to some limitations. First, the results of a single-center study
242 may not be generalize to all institutions. However, due to the increase of infectious patients
243 and the strained medical resources, the study conducted in a COVID-19-designated hospital
244 reflects the current situation of diagnosis and treatment of severe COVID-19 patients in most
245 designated hospitals in Wuhan. Second, the study is a descriptive research. Further large-scale
246 prospective studies are needed to explore the impact of diagnostic measures and supportive
247 treatments on disease prognosis. Third, we are unable to completely address the residual
248 confounding and bias because of the nature of the observational study. Conclusions on the
249 effect of treatments should be considered with caution. High-quality clinical interventional

250 studies are warranted. Finally, patients included in our study were only treated with high-flow
251 ventilation. The benefits of invasive ventilation, prone positioning, and the ECMO on disease
252 prognosis should be further investigated.
253
254 **Conclusions**
255 In summary, we observed 2019-nCoV infected patients with moderate-to-severe ARDS had
256 higher mortality rates. In addition, our findings indicated that current clinical treatments might
257 not have a significant effect on in-hospital mortality in COVID-19 patients with ARDS. In
258 clinical practice, clinicians should pay more attention toward COVID-19 patients who were at
259 high risk of ARDS and strengthen supportive care.
260

Acknowledgement: We deeply regret and mourn the passing of our dear colleague Dr. Wenliang Li. We would like to express our deepest respect to him and all colleagues who are currently fighting the outbreak of 2019-nCoV.

Conflict of Interest Disclosures: None.

Founding/Support: Dr. Yu is supported by the Health and Family Planning Commission of Wuhan Municipality, grant number WX18A02.

Role of the Founder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Authors Contributions: Dr. Chen and Dr. Yu had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Liu, Sun, Chen, Yu.

Acquisition, analysis, or interpretation of data: Sun, Liu, Chen.

Drafting of the manuscript: Liu.

Critical revision of the manuscript for important intellectual content: Wang, Zhang, Chen, Yu.

Statistical analysis: Chen.

Obtained funding: Yu.

Supervision: Chen, Yu.

280 References
281

282 1. The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team QL. An
283 Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province,
284 2019−2020. 2020;2(5):79-80.
285 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia
286 in China, 2019. *N Engl J Med.* 2020.
287 3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
288 Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020.
289 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
290 coronavirus in Wuhan, China. *Lancet.* 2020.
291 5. WHO. Novel coronavirus – Thailand (ex-China). http://www.who.int/csr/don/14-
292 january-2020-novel-coronavirus-thailand/en/. Published January 14, 2020. Accessed
293 February 12, 2020.
294 6. WHO. Novel coronavirus – Japan (ex-China). http://www.who.int/csr/don/17-january-
295 2020-novel-coronavirus-japan-ex-china/en/ Published January 17, 2020. Accessed
296 February 12, 2020.
297 7. WHO. Novel coronavirus – Republic of Korea (ex-China).
298 http://www.who.int/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-
299 china/en/. Published January 21, 2020. Accessed February 12, 2020.
300 8. Centers for Disease Control and Prevention. First Travel-related Case of 2019 Novel
301 Coronavirus Detected in United States.
302 https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html.
303 Published January 21, 2020. Accessed February 12, 2020.
304 9. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With
305 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020.
306 10. World Health Organization. Clinical management of severe acute respiratory infection
307 when novel coronavirus (nCoV) infection is suspected: interim guidance.
308 https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-
309 cov.pdf?sfvrsn=bc7da517_2. Published January 28, 2020. Accessed February 12, 2020.
310 11. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the
311 Berlin Definition. *JAMA.* 2012;307(23):2526-2533.
312 12. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent
313 insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016;14(8):523-534.
314 13. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits
315 both epidemic and zoonotic coronaviruses. *Sci Transl Med.* 2017;9(396).
316 14. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir
317 and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat*
318 *Commun.* 2020;11(1):222.
319 15. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in
320 severe acute respiratory syndrome. *Clin Exp Immunol.* 2004;136(1):95-103.
321 16. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid
322 treatment for 2019-nCoV lung injury. *Lancet.* 2020.
323 17. Alejandria MM, Lansang MA, Dans LF, Mantaring JB, 3rd. Intravenous

immunoglobulin for treating sepsis, severe sepsis and septic shock. *Cochrane Database Syst Rev.* 2013(9):CD001090.

327 **Table 1. Baseline Characteristics of Patients Infected With 2019-nCoV**

	No. (%)			
	Total (*n* = 109)	**Non-ARDS (*n* = 56)**	**ARDS (*n* = 53)**	***P*-value[a]**
Age, median (IQR), y	55 (43-66)	49 (37-59)	61 (52-70)	**<0.001**
Male	59 (54.1)	31 (55.4)	28 (52.8)	0.79
Entering complaint				
Fever	90 (82.6)	48 (85.7)	42 (79.2)	0.37
Dry cough	67 (61.5)	36 (64.3)	31 (58.5)	0.53
Fatigue	62 (56.9)	26 (46.4)	36 (67.9)	**0.02**
Stethalgia	7 (6.4)	4 (7.1)	3 (5.7)	0.75
Diarrhea	12 (11.0)	6 (10.7)	6 (11.3)	0.92
Comorbidities				
COPD	4 (3.7)	2 (3.6)	2 (3.8)	>0.99
Hypertension	37 (33.9)	16 (28.6)	21 (39.6)	0.22
Diabetes	12 (11.0)	1 (1.8)	11 (20.8)	**0.002**
Cardiovascular disease	7 (6.4)	4 (7.1)	3 (5.7)	>0.99
Cerebrovascular disease	6 (5.5)	0 (0.0)	6 (11.3)	**0.01**
Chronic kidney disease	10 (9.2)	2 (3.6)	8 (15.1)	**0.049**
Onset of symptom to fever clinics, median (IQR), d	4 (2-6)	4 (2-7)	4 (2-6)	0.88
Onset of symptom to hospital admission, median (IQR), d	7 (5-9)	7 (5-9)	7 (5-9)	0.58
Hospital stays, median (IQR), d	15 (11-24)	15 (9-27)	16 (11-23)	0.41
Nucleic acid test (+) in fever clinics	27 (24.8)	12 (21.4)	15 (28.3)	0.41
Bilateral involvement of chest radiographs	100 (91.7)	47 (83.9)	53 (100)	**0.002**
Fever clinics treatment				
Antibiotics	105 (96.3)	55 (98.2)	50 (94.3)	0.35
Antivirus	105 (96.3)	55 (98.2)	50 (94.3)	0.35
Glucocorticoid therapy	43 (39.4)	20 (35.7)	23 (43.4)	0.41
Intravenous immunoglobulin	32 (29.4)	19 (33.9)	13 (24.5)	0.28

In-patient treatment				
Antibiotics	106 (97.2)	53 (94.6)	53 (100.0)	0.24
Antivirus	107 (98.2)	55 (98.2)	52 (98.1)	>0.99
Glucocorticoid therapy	72 (66.1)	35 (62.5)	37 (69.8)	0.42
Intravenous immunoglobulin	61 (56.0)	32 (57.1)	29 (54.7)	0.80
High-flow nasal ventilation	28 (25.7)	2 (3.6)	26 (49.1)	**<0.001**
Death	31 (28.4)	5 (8.9)	26 (49.1)	**<0.001**

Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;
[a] *p* values indicate differences between non-ARDS and ARDS patients.

331 **Table 2. Severity of Illness Scores, Blood Gas Analysis, and Laboratory Findings**

	Normal range	Median (IQR)			*P*-value[a]
		Total (*n* = 109)	Non-ARDS (*n* = 56)	ARDS (*n* = 53)	
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	0 (0-1)	1 (0-2)	**<0.001**
SOFA	NA	2 (1-4)	1 (0-1)	4 (2-5)	**<0.001**
APACHE II	NA	4 (2-8)	2 (1-3)	8 (5-10)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.3 (0.8-2.0)	1.1 (0.8-1.6)	1.6 (1.1-2.2)	**<0.001**
PaO_2 : FiO_2, mm Hg	400-500	296 (142-435)	475 (398-524)	145 (108-250)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, $\times 10^9$/L	3.5-9.5	5.2 (4.0-7.0)	4.9 (3.8-6.2)	5.4 (4.5-8.0)	0.053
Neutrophil count, $\times 10^9$/L	1.8-6.3	3.6 (2.8-5.6)	3.2 (2.4-4.2)	4.1 (3.1-7.1)	**0.004**
Lymphocyte count, $\times 10^9$/L	1.1-3.2	0.9 (0.5-1.2)	1.0 (0.8-1.4)	0.7 (0.4-1.1)	**<0.001**
C-reactive protein, mg/dL	0-0.5	3.1 (1.1-5.4)	2.0 (0.9-3.2)	4.9 (2.7-6.5)	**<0.001**
Procalcitonin, ng/mL	<0.05	0.1 (0.1-0.2)	0.1 (0.0-0.1)	0.1 (0.1-0.4)	**<0.001**
Blood urea nitrogen, mmol/L	2.8-8	4.3 (3.3-6.5)	3.5 (2.9-4.8)	5.5 (4.0-7.1)	**<0.001**
Creatinine, μmol/L	57-111	65 (55-82)	64 (52-80)	67 (55-83)	0.42
Total bilirubin, mmol/L	0-21	9.0 (6.5-13.4)	8.3 (6.8-11.7)	10.5 (6.2-14.8)	0.23
Alanine aminotransferase, U/L	9-50	23 (15-36)	23 (14-41)	24 (16-31)	0.82
Aspartate aminotransferase, U/L	15-40	30 (21-40)	29 (19-38)	31 (25-44)	0.17
Fibrinogen, g/L	2-4	3.1 (2.7-3.6)	2.9 (2.7-3.3)	3.4 (2.9-3.9)	**0.001**
D-dimer, mg/L	0-500	(300-1178)	370 (250-650)	940 (470-1905)	**<0.001**
Lactate dehydrogenase, U/L	135-225	238 (185-341)	209 (183-267)	264 (190-448)	**0.011**
Creatine kinase, U/L	<190	91 (52-178)	100 (53-183)	83 (49-169)	0.29
Creatine kinase–MB, U/L	<25	9.0 (6.1-14.8)	8.5 (6.0-12.5)	10.4 (7.0-15.1)	0.28

332 Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO_2, fraction of

333 inspired oxygen; IQR, interquartile range; NA, not available; PaO_2, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment
334 [a] *p* values indicate differences between non-ARDS and ARDS patients.
335

336 **Table 3. Clinical Characteristics, Laboratory Findings, and Treatment According to The Severity of ARDS**

	Normal range	Median (IQR)			*P*-value[a]
		Mild ARDS (*n* = 19)	Moderate ARDS (*n* = 24)	Severe ARDS (*n* = 10)	
Age, y	NA	52 (46-63)	65 (57-70)	67 (55-71)	**0.04**
Severity of illness scores and blood gas analysis on admission to hospital					
CURB-65	NA	0 (0-1)	1 (1-2)	2 (1-3)	**<0.001**
SOFA	NA	2 (2-3)	4 (3-5)	6 (5-6)	**<0.001**
APACHE II	NA	3 (2-6)	8 (7-12)	10 (8-13)	**<0.001**
Lactate, mmol/L	0.5-1.6	1.2 (0.8-1.7)	1.8 (1.1-2.3)	5.2 (2.0-10.0)	**<0.001**
PaO_2 : FiO_2, mm Hg	400-500	276 (247-280)	140 (117-153)	85 (57-88)	**<0.001**
Laboratory findings on admission to hospital					
White blood cell count, ×109/L	3.5-9.5	4.6 (3.8-5.0)	7.3 (5.2-10.5)	7.0 (4.6-8.0)	**0.006**
Neutrophil count, ×109/L	1.8-6.3	3.2 (2.3-3.8)	6.0 (4.2-9.0)	5.3 (3.7-7.3)	**0.002**
Lymphocyte count, ×109/L	1.1-3.2	0.9 (0.7-1.3)	0.6 (0.4-0.9)	0.5 (0.4-0.8)	**0.045**
C-reactive protein, mg/dL	0-0.5	4.1 (2.2-5.9)	4.1 (1.9-9.7)	6.7 (5.5-12.2)	**0.027**
Procalcitonin, ng/mL	<0.05	0.1 (0.1-0.2)	0.2 (0.1-0.6)	0.3 (0.2-1.5)	0.09
Blood urea nitrogen, mmol/L	2.8-8	4.5 (3.5-6.1)	5.6 (4.5-7.7)	7.1 (6.0-8.0)	**0.03**
Creatinine, μmol/L	57-111	67 (58-74)	65 (54-99)	70 (55-80)	0.89
Total bilirubin, mmol/L	0-21	7.9 (5.8-10.4)	13.2 (9.3-18.6)	13.2 (6.2-13.5)	0.07
Alanine aminotransferase, U/L	9-50	24 (15-34)	24 (21-27)	21 (15-32)	0.90
Aspartate aminotransferase, U/L	15-40	29 (21-43)	34 (27-44)	29 (27-36)	0.45
Fibrinogen, g/L	2-4	3.3 (2.8-3.6)	3.4 (2.9-4.3)	3.6 (3.4-4.1)	0.41
D-dimer, mg/L	0-500	330 (220-798)	1220 (695-4035)	1385 (985-7550)	**<0.001**
Lactate dehydrogenase, U/L	135-225	190 (166-238)	347 (255-504)	458 (286-549)	**0.001**
Creatine kinase, U/L	<190	69 (44-119)	92 (58-185)	66 (53-188)	0.49

Creatine kinase–MB, U/L	<25	8.0 (6.5-11.6)	11.1 (6.8-16.1)	10.9 (8.9-12.0)	0.37
In-patient treatment, *n* (%)					
Ribavirin	NA	18 (94.7)	18 (75.0)	10 (100.0)	0.08
Oseltamivir	NA	5 (26.3)	8 (33.3)	1 (10.0)	0.43
Arbidol	NA	3 (15.8)	2 (8.3)	1 (10.0)	0.85
Glucocorticoid therapy	NA	9 (47.4)	21 (87.5)	7 (70.0)	**0.02**
Intravenous immunoglobulin	NA	13 (68.4)	9 (37.5)	7 (70.0)	0.08
High-flow nasal ventilation, *n* (%)	NA	1 (5.3)	19 (79.2)	6 (60.0)	**<0.001**
Hospital stays, d	NA	18 (13-25)	18 (15-25)	11 (10-13)	**0.03**
Death, *n* (%)	NA	1 (5.3)	15 (62.5)	10 (100.0)	**<0.001**

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute respiratory distress syndrome; FiO_2, fraction of inspired oxygen; IQR, interquartile range; NA, not available; PaO_2, partial pressure of oxygen; SOFA, Sequential Organ Failure Assessment

[a] *p* values indicate differences among mild, moderate, and severe ARDS patients.

341 **Figure legends**

342

343 Figure 1. Timeline charts illustrate the laboratory parameters in 109 patients with COVID-19 (56 non-ARDS and 53 ARDS) on day 1, day 3, day

344 7, and day 14 after admission. The dash lines in black show the upper normal limit of each parameter, and the dash line in red shows the lower

345 normal limit of lymphocyte count.

346 * P <0.05 for non-ARDS *vs*. ARDS.

347

348 Figure 2. Kaplan-Meier survival curves for 53 COVID-19 patients concurrent ARDS. (A) Ribavirin; (B) Oseltamivir; (C) Arbidol; (D)

349 Glucocorticoid therapy; (E) Intravenous immunoglobulin.


P = 0.06
White blood cell count, ×10⁹/L
ARDS
Non-ARDS
P = 0.03
Neutrophil count, ×10⁹/L
ARDS
Non-ARDS
P <0.01
Lymphocyte count, ×10⁹/L
Non-ARDS
ARDS
P <0.01
C-reactive protein, mg/dL
ARDS
Non-ARDS
P = 0.04
Procalcitonin, ng/mL
ARDS
Non-ARDS
P = 0.11
Total bilirubin, mmol/L
ARDS
Non-ARDS
P = 0.18
Creatinine, μmol/L
ARDS
Non-ARDS
P = 0.03
D-dimer, mg/L
ARDS
Non-ARDS
P = 0.24
Creatine kinase–MB, U/L
ARDS
Non-ARDS
Day 1
Day 3
Day 7
Day 14


A
Ribavirin No Yes
Survival probability
p = 0.42
Follow−up, days
Number at risk
Ribavirin
7 7 6 4 4 4
46 42 25 15 7 3
B
Oseltamivir No Yes
p = 0.095
Number at risk
Oseltamivir
39 35 20 11 4 1
14 14 11 8 7 6
C
Arbidol No Yes
p = 0.19
Number at risk
Arbidol
47 43 30 19 11 7
6 6 1 0 0 0
D
Glucocorticoid therapy No Yes
p = 0.56
Number at risk
Glucocorticoid therapy
16 15 8 4 2 2
37 34 23 15 9 5
E
Intravenous immunoglobulin No Yes
p = 0.51
Number at risk
Intravenous immunoglobulin
24 23 17 12 7 5
29 26 14 7 4 2